Revolution Medicines, Inc. ((RVMD)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Revolution Medicines, Inc. is conducting a Phase 1/1b clinical study titled ‘Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors.’ The study aims to assess the safety and tolerability of the drug RMC-9805, both as a standalone treatment and in combination with RMC-6236, for adults with KRAS G12D-mutant solid tumors, including non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
The interventions being tested are RMC-9805 and RMC-6236, both administered as oral tablets. RMC-9805 is being explored for its potential to treat KRAS G12D-mutant solid tumors, either alone or in combination with RMC-6236, to enhance therapeutic outcomes.
The study follows a non-randomized, parallel intervention model with no masking, focusing on treatment as its primary purpose. It includes two experimental arms: one for RMC-9805 monotherapy and another for the combination of RMC-9805 and RMC-6236, both undergoing dose exploration and expansion.
The study began on August 31, 2023, with its primary completion and estimated overall completion expected by August 27, 2025. These dates are crucial for tracking the study’s progress and anticipating potential market impacts.
This update could influence Revolution Medicines’ stock performance positively, as successful outcomes might enhance investor confidence and position the company competitively in the oncology market. The focus on KRAS mutations, a challenging target in cancer treatment, underscores the study’s significance in the industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.